China State Council Unveils Pro-Pharma Policies, But Will They Work?
This article was originally published in PharmAsia News
In a new policy push, China's Cabinet has listed major goals to propel the country to become the next destination for pharma innovation, with antibodies, therapeutic vaccines and peptides among the priority fields. But doubts remain given scant details on how regulators will work together to achieve the lofty goals.
You may also be interested in...
Biogen/Eisai’s US filing of aducanumab for Alzheimer’s has a ripple effect in China, where a leading biomedical researcher has publicly questioned data for the country’s first approved drug for the disease, GV971.
From cell therapy to digital health, from fast follower to innovator, China continues to gain traction with global health companies, underscored by its early emergence from the global pandemic and focus on certain technologies, with Boehringer Ingelheim the latest to be attracted.
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.